Ulcerative Colitis Therapeutics Market to Reach US$ 7.9 Bn by 2027 | Key Growth Drivers and Market Insights

The global ulcerative colitis therapeutics market is anticipated to rise at a CAGR of 5.1% from 2021 to 2027. In 2020, revenue from ulcerative colitis therapeutics was US$ 5.6 Bn, which is expected to reach US$ 7.9 Bn by 2027. The specific cause of ulcerative colitis is unknown; however genetic causes, environmental changes, or immune system failure are all possibilities. Simple healthy practices such as having short meals throughout the day, staying hydrated, avoiding greasy foods, and reducing high-fiber food intake can help prevent ulcerative colitis.

Therapy for ulcerative colitis has two basic objectives. The first is to reduce symptom severity and improve patient comfort, while also promoting gut repair. The second goal is to prevent further flare-ups. The goal of treatment is to reduce and control the disease's indications and symptoms.

The global ulcerative colitis therapeutics market is primarily driven by an increase in the incidence of inflammatory bowel diseases, increase in ulcerative colitis cases, and development of ulcerative colitis-specific medications by a large number of key companies.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7286

Key Takeaways from Market Study

• Global ulcerative colitis therapeutics market to reach US$ 19.9 Bn by 2027.
• Ulcerative proctitis segment is projected to reach around US$ 2.1 Bn by 2027.
• Market in Europe to record 4.2% CAGR over the forecast period of 2021-2027.
• Market in China forecast to reach US$ 1.4 Bn valuation by 2027.

“Increasing product releases & approvals, rise in active clinical studies, and growing research & development activities for the treatment of ulcerative colitis illness are likely to fuel market growth over the coming years,” says a Fact.MR analyst

Winning Strategy

Key market players are focusing on the development of novel treatments for severe conditions of ulcerative colitis. Companies are involved in the development of novel drugs for the treatment of ulcerative colitis.

To enter into new markets and obtain high market share, key firms are focusing their efforts on product expansions and the development of innovative therapies, particularly in emerging economies. Alliances are being formed regularly to diversify product portfolios and boost market share.

For instance,

• In 2019, Abbvie Company finalized the acquisition of Allergan, allowing it to expand its pharmaceutical range and provide patients with more advanced therapies. Allergen created a monoclonal antibody known as brazikumab, which is used to treat ulcerative colitis and Crohn's disease.
• In April 2021, Arena Pharmaceuticals, Inc. started a phase II clinical trial to see if oral etrasimod is an effective therapy for adults with moderately active ulcerative colitis.

Get Customization on this Report for Specific Research Solutions :https://www.factmr.com/connectus/sample?flag=S&rep_id=7286

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global ulcerative colitis therapeutics market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2027.

The study divulges essential insights on the market on the basis of disease type (ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis) and route of administration (oral and injectables), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).

Key Companies Profiled-

Abbott Laboratories, Inc.; AstraZeneca PLC; Avaxia Biologics, Inc.; BioLineRx Ltd.; Astellas Pharma, Inc.; Cosmo Pharmaceuticals NV; AbbVie, Inc.; Amgen, Inc.

Industry News-

In May 2021, The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's Zeposia (ozanimod) for the treatment of individuals with moderately to highly active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).

Explore More Related Studies Published by Fact.MR Research:

The global nerve repair and regeneration market is projected to rise at a stellar CAGR of 11% from 2022 to 2026. Currently, the market is valued at US$ 8 billion and is anticipated to reach US$ 12 billion by the end of 2026.

Expanding at a CAGR of 6%, the global patient warming devices market is projected to increase from a valuation of US$ 2 billion in 2022 to US$ 3 billion by the end of 2026.

At present, the global psychotic disorder treatment market accounts for US$ 13.6 billion and is projected to surge past a valuation of US$ 24.5 billion by the end of 2032.

The global PCR and real-time PCR molecular diagnostics market is predicted to progress at a CAGR of 4.1% from 2023 to 2033. The market is valued at US$ 5 billion in 2023 and is thereby expected to reach US$ 7.5 billion by 2033-end.

The global Esophageal Stents Market is expected to reach USD 203 million by 2035, up from USD 89 million in 2024. During the forecast period, the industry is projected to expand at a CAGR of 8.0%.

About Fact.MR:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: [email protected]

Follow Us: LinkedIn | Twitter | Blog

Meta Description

Latest industry report by Fact.MR on the ulcerative colitis therapeutics market opines steady growth with the emergence of efficient and modern therapies.